243 related articles for article (PubMed ID: 35605249)
1. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
Ikeda M; Hayes CK; Schaller SJ; Longnecker R
Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
[TBL] [Abstract][Full Text] [Related]
2. Two Pathways of p27
Sora RP; Ikeda M; Longnecker R
mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
[TBL] [Abstract][Full Text] [Related]
3. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
Bieging KT; Amick AC; Longnecker R
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507
[TBL] [Abstract][Full Text] [Related]
5. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.
Ma SD; Tsai MH; Romero-Masters JC; Ranheim EA; Huebner SM; Bristol JA; Delecluse HJ; Kenney SC
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077657
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
Bieging KT; Swanson-Mungerson M; Amick AC; Longnecker R
Cell Cycle; 2010 Mar; 9(5):901-8. PubMed ID: 20160479
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
Fish K; Chen J; Longnecker R
Blood; 2014 Jan; 123(4):530-40. PubMed ID: 24174629
[TBL] [Abstract][Full Text] [Related]
8. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
Cen O; Longnecker R
Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
[TBL] [Abstract][Full Text] [Related]
10. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
[TBL] [Abstract][Full Text] [Related]
12. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
Wasil LR; Wei L; Chang C; Lan L; Shair KH
J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
Bultema R; Longnecker R; Swanson-Mungerson M
Oncogene; 2009 Mar; 28(11):1471-6. PubMed ID: 19182823
[TBL] [Abstract][Full Text] [Related]
14. Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis.
Sommermann T; Yasuda T; Ronen J; Wirtz T; Weber T; Sack U; Caeser R; Zhang J; Li X; Chu VT; Jauch A; Unger K; Hodson DJ; Akalin A; Rajewsky K
Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14421-14432. PubMed ID: 32522871
[TBL] [Abstract][Full Text] [Related]
15. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
16. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
[TBL] [Abstract][Full Text] [Related]
18. A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma.
Bieging KT; Fish K; Bondada S; Longnecker R
Blood; 2011 Dec; 118(26):6849-59. PubMed ID: 22039254
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.
Dargart JL; Fish K; Gordon LI; Longnecker R; Cen O
Antiviral Res; 2012 Jul; 95(1):49-56. PubMed ID: 22609829
[TBL] [Abstract][Full Text] [Related]
20. Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma.
Vockerodt M; Vrzalikova K; Ibrahim M; Nagy E; Margielewska S; Hollows R; Lupino L; Tooze R; Care M; Simmons W; Schrader A; Perry T; Abdullah M; Foster S; Reynolds G; Dowell A; Rudzki Z; Krappmann D; Kube D; Woodman C; Wei W; Taylor G; Murray PG
J Pathol; 2019 Jun; 248(2):142-154. PubMed ID: 30666658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
